SERPINE1 and leukemia: Studies have shown that SERPINE1 inhibitors exhibit anti-leukemia effects in mice model of CML, and the combination of SERPINE1 inhibitor and TKI achieves a higher molecular response rate in CML patients than monotherapy with TKIs [47, 48].